MA31178B1 - مشتقات 3 –الأميني-بيرولو [3،4-c] بيرازول-5- (1h,4h, 6h) كمثبطات pkc. - Google Patents

مشتقات 3 –الأميني-بيرولو [3،4-c] بيرازول-5- (1h,4h, 6h) كمثبطات pkc.

Info

Publication number
MA31178B1
MA31178B1 MA32158A MA32158A MA31178B1 MA 31178 B1 MA31178 B1 MA 31178B1 MA 32158 A MA32158 A MA 32158A MA 32158 A MA32158 A MA 32158A MA 31178 B1 MA31178 B1 MA 31178B1
Authority
MA
Morocco
Prior art keywords
pyrolo
pyrazol
derivatives
amino
pharmaceutically acceptable
Prior art date
Application number
MA32158A
Other languages
English (en)
French (fr)
Inventor
Hui Li
Seiji Nukui
Stephanie Anne Scales
Min Teng
Chunfeng Yin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA31178B1 publication Critical patent/MA31178B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA32158A 2007-02-07 2009-08-07 مشتقات 3 –الأميني-بيرولو [3،4-c] بيرازول-5- (1h,4h, 6h) كمثبطات pkc. MA31178B1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88874907P 2007-02-07 2007-02-07
US98908607P 2007-11-19 2007-11-19
US2096508P 2008-01-14 2008-01-14
PCT/IB2008/000297 WO2008096260A1 (en) 2007-02-07 2008-02-04 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors

Publications (1)

Publication Number Publication Date
MA31178B1 true MA31178B1 (ar) 2010-02-01

Family

ID=39493354

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32158A MA31178B1 (ar) 2007-02-07 2009-08-07 مشتقات 3 –الأميني-بيرولو [3،4-c] بيرازول-5- (1h,4h, 6h) كمثبطات pkc.

Country Status (20)

Country Link
US (6) US8183255B2 (ar)
EP (1) EP2118112B1 (ar)
JP (1) JP5161245B2 (ar)
KR (1) KR101060892B1 (ar)
AP (1) AP2009004958A0 (ar)
AU (1) AU2008212625B2 (ar)
BR (1) BRPI0807346B8 (ar)
CA (1) CA2677572C (ar)
CR (1) CR10968A (ar)
DO (1) DOP2009000201A (ar)
EA (1) EA017937B1 (ar)
EC (1) ECSP099569A (ar)
HK (1) HK1139130A1 (ar)
IL (1) IL200270A (ar)
MA (1) MA31178B1 (ar)
MX (1) MX2009008546A (ar)
NZ (1) NZ578876A (ar)
TN (1) TN2009000331A1 (ar)
WO (1) WO2008096260A1 (ar)
ZA (1) ZA200906032B (ar)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008096260A1 (en) 2007-02-07 2008-08-14 Pfizer Inc. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012112674A2 (en) * 2011-02-15 2012-08-23 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN102093366B (zh) * 2011-03-04 2012-11-28 中国医学科学院医药生物技术研究所 双环氨基吡唑类化合物及其在抗柯萨奇病毒中的应用
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
CA2867760C (en) 2012-04-04 2021-10-05 Rigel Pharmaceuticals, Inc. Indolizinyl derivatives as protein kinase c inhibitors and uses thereof
MX358172B (es) * 2012-05-03 2018-08-08 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6421170B2 (ja) 2013-03-14 2018-11-07 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
EP3145931B1 (en) * 2014-05-23 2021-03-31 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
CN106727582B (zh) * 2015-11-20 2020-06-12 深圳明赛瑞霖药业有限公司 自身免疫疾病的治疗
AU2016355303B2 (en) * 2015-11-20 2021-10-07 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
CA3030429A1 (en) * 2016-07-14 2018-01-18 Mingsight Pharmaceuticals, Inc. Treatment of cancer
US11104679B2 (en) 2017-05-25 2021-08-31 Mingsight Pharmaceuticals, Inc. PKC inhibitor solid state forms
JP7362600B2 (ja) 2017-10-11 2023-10-17 エフ． ホフマン－ラ ロシュ アーゲー Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物
US20210069194A1 (en) * 2018-01-17 2021-03-11 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
JP2022517740A (ja) * 2018-12-28 2022-03-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
WO2022261214A1 (en) * 2021-06-09 2022-12-15 Mingsight Pharmaceuticals, Inc. Compositions comprising pkc-beta inhibitors and processes for the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113176A (pt) * 2000-08-10 2003-06-17 Pharmacia Italia Spa Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US8067591B2 (en) 2005-01-10 2011-11-29 Agouron Pharmaceuticals, Inc. Pyrrolopyrazole, potent kinase inhibitors
WO2008096260A1 (en) 2007-02-07 2008-08-14 Pfizer Inc. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors

Also Published As

Publication number Publication date
EP2118112B1 (en) 2015-07-08
AU2008212625B2 (en) 2012-07-19
US20120202809A1 (en) 2012-08-09
US11220518B2 (en) 2022-01-11
BRPI0807346B8 (pt) 2021-05-25
KR20090119883A (ko) 2009-11-20
US20170217991A1 (en) 2017-08-03
AP2009004958A0 (en) 2009-08-31
DOP2009000201A (es) 2009-08-31
US11780853B2 (en) 2023-10-10
EA017937B1 (ru) 2013-04-30
EA200970670A1 (ru) 2010-02-26
US8877761B2 (en) 2014-11-04
CR10968A (es) 2009-08-27
US8183255B2 (en) 2012-05-22
MX2009008546A (es) 2009-10-08
AU2008212625A1 (en) 2008-08-14
BRPI0807346B1 (pt) 2020-01-07
US20200002359A1 (en) 2020-01-02
ZA200906032B (en) 2013-03-27
TN2009000331A1 (fr) 2010-12-31
CA2677572A1 (en) 2008-08-14
CA2677572C (en) 2012-12-18
JP2010518069A (ja) 2010-05-27
US9518060B2 (en) 2016-12-13
HK1139130A1 (en) 2010-09-10
IL200270A (en) 2014-07-31
WO2008096260A1 (en) 2008-08-14
IL200270A0 (en) 2010-04-29
KR101060892B1 (ko) 2011-08-31
NZ578876A (en) 2012-12-21
JP5161245B2 (ja) 2013-03-13
US20150099743A1 (en) 2015-04-09
US20220089613A1 (en) 2022-03-24
BRPI0807346A2 (pt) 2016-07-26
EP2118112A1 (en) 2009-11-18
ECSP099569A (es) 2009-09-29
US20100130501A1 (en) 2010-05-27
US10316045B2 (en) 2019-06-11

Similar Documents

Publication Publication Date Title
MA31178B1 (ar) مشتقات 3 –الأميني-بيرولو [3،4-c] بيرازول-5- (1h,4h, 6h) كمثبطات pkc.
MX2009010951A (es) Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c.
US6624202B2 (en) Inhibitors of copper-containing amine oxidases
KR102266509B1 (ko) 면역-관련 및 염증성 질환의 치료
MA33614B1 (ar) تركيبات بنزوكسبين مثبطات pi3k وطرق استخدامها
MA31146B1 (fr) Composes inhibant la phosphoinositide 3 kinase et procedes d'utilisation
AU2001282163A1 (en) Inhibitors of copper-containing amine oxidases
MA31260B1 (ar) ليميدازولين-اندولات لعلاج أمراض التكاثري.
MX2008011013A (es) Composiciones y metodos para tratar enfermedades caracterizadas por proliferacion celular y angiogenesis.
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
CA2451569A1 (en) Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
CA2530006A1 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
DK1326613T4 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
MA29462B1 (fr) Imidazoquinolines utilises en tant qu'inhibiteurs de kinase lipidique
MA32135B1 (ar) مثبطات البيم كيناز و طرق استخدامها
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
JPH09505082A (ja) Ｔｎｆ放出の阻害剤としてのイソオキサゾリン
KR20080096657A (ko) 인지 장애의 치료 방법
BR0314314A (pt) Derivados do éter 4-pirrolidina-fenil-benzìlico
UA96618C2 (en) 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
WO2006108682A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use as anti-fungal agents
WO2005080319A1 (en) Hydrazino alcohol derivatives useful as inhibitors of copper-containing amine oxidases
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора